Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Gastroenterology. 2020 Oct 29;160(3):781–796. doi: 10.1053/j.gastro.2020.10.036

Figure 4. Immune effects of combination chemo-immunotherapy.

Figure 4.

(A) The proportion of intratumoral T cells in treated GAS-KO tumors (n = 8-13/group).

(B) CD8 immunostaining on treated tumors.

(C) Frequency of effector cytokine-secreting CD8+ T cells (n = 3/group).

(D) CD11b immunostaining on treated tumors.

(E) The proportion of MDSCs in treated GAS-KO tumors (n = 8-13/group).

(F) Linear regression analyses between tumor area and the percentage of CD8+ T cells and PMN-MDSCs in GAS-KO tumors (n = 44). r2 and P-values are shown.

(G) MFI (mean fluorescence intensity) of PD-L1 expressed on EpCAM+ cells isolated from GAS-KO tumors treated as indicated (n = 3-5/group).

Scale bars, 50 μm. Mean ± SEM. Student’s t-test. *P < .05; **P < .01; ***P < .001.